Fig. 4.
Change in (A) skin pain visual analogue scale (VAS) and (B) the proportions of patients achieving Skin Pain VAS (0) when treated with ixekizumab (IXE) or ustekinumab (UST) for 52 weeks. *p < 0.05, **p < 0.01, ***p < 0.001, all vs UST by (A) Wilcoxon rank sum or (B) Fisher’s exact test. Skin pain VAS scores previously reported for weeks 0–24 (12). mBOCF: modified baseline observation carried forward; NRI: non-responder imputation.
